Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment

Journal of Infectious Diseases

Volumn 177, Issue 5, 1998, Pages 1382-1385

  Niesters, Hubert G M ^a   Honkoop, Pieter ^b   Haagsma, Elizabeth B ^b   De Man, Robert A ^b   Schalm, Solko W ^b   Osterhaus, Albert D M E ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FAMCICLOVIR; ISOLEUCINE; LAMIVUDINE; METHIONINE; VALINE;

AMINO ACID SEQUENCE; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS GENE; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0031900989     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517819     Document Type: Article

References (15)

1. Schalm SW, De Man RA, Heijtink RA, Niesters HG. New nucleoside analogues for chronic hepatitis B. J Hepatol 1995;22:52-6.
2. Dyer JR, Gilliam BL, Eron JJ Jr, Grosso L, Cohen MS, Fiscus SA. Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture. J Virol Methods 1996;60:161-70.
3. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
4. Honkoop P, De Man RA, Heijtink RA, Schalm SW. Hepatitis B reactivation after lamivudine. Lancet 1995;346:1156-7.
5. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711-3.
6. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:20-2.
7. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996 348:1212-5.
8. Honkoop P, Niesters HGM, De Man RA, Osterhaus ADME, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B: incidence and patterns. J Hepatol 1997;26:1393-5.
9. Fischer KP, Tyrrell DL. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] in vitro. Antimicrob Agents Chemother 1996;40:1957-60.
10. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in hepatitis B virus RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatplogy 1996;24:714-7.
11. Boucher CA, Cammack N, Schipper P, et al. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993; 37: 2231-4.
12. Gao Q, Gu Z, Parniak MA, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother 1993;37:1390-2.
13. Kavlick MF, Shirasaka T, Kojima E, et al. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2',3'-dideoxy-3'-thiacytidine. Antiviral Res 1995;28:133-46.
14. Schuurman R, Nijhuis M, Van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-9.
15. Poch O, Sauvaget I, Delarue M, Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 1989; 8:3867-74.